TCG Crossover
Status
ACTIVE
Global HQ
Palo Alto, United States
Countries of investment
- United States
- United Kingdom
- Switzerland
- Germany
Investment stages
- Series A
- Series B
- Series C
- Growth
- IPO
Industries
- Biotechnology
- Life Sciences
- Pharma
- Biologics
About
TCG Crossover targets high-conviction biotech and pharmaceutical ventures with transformative therapeutic potential. The firm bridges the gap between private and public funding, supporting companies from advanced clinical stages through commercialization and IPO readiness across the United States and Europe.
TCG Crossover targets high-conviction biotech and pharmaceutical ventures with transformative therapeutic potential. The firm bridges the gap between private and public funding, supporting companies from advanced clinical stages through commercialization and IPO readiness across the United States and Europe.
Investment Thesis
TCG Crossover invests in innovative biopharma and life sciences companies operating at the intersection of late-stage private and public markets.
Manager's Experience
Founded in 2021 by Chen Yu, a former Managing Partner at Vivo Capital with over 20 years in public and private life sciences investing. TCGX has raised $3.1B in total, with exits including Tourmaline Bio's $1.4B sale to Novartis and ADARx's IPO.
Team
Managing Partner – Chen Yu
Managing Partner – Cariad Chester
Partner – Giuliano Marostica
Venture Partner – Dandan Dong
Associate (Bioengineer) – George Feng
Analyst
Portfolio
Revolution Medicines
IGM Biosciences
Recursion
Kallyope